In experimental DN the DPP-4 inhibitor linagliptin reduced albuminuria and ameliorated glomerulosclerosis and interstitial fibrosis, independently of glucose control (Kanasaki, 2018). The gene discussed is DPP4; the disease is liver dysplastic nodule.